* A corporate client of Hybridan LLP.
** Potential means Intention to Float (ITF) or similar announcement has been made.
***Arranged by type of listing and date of announcement.
****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication.
Admissions:
None
Delistings:
None
What’s baking in the oven?
It's a little empty
Banquet Buffet****
Arecor Therapeutics 62.50p £22.47m (AREC.L)
The clinical stage biotech Company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases, announces the publication of clinical data from its AT278-104 study published in the peer-reviewed Diabetes, Obesity & Metabolism. The study demonstrated that AT278, Arecor's investigational ultra-concentrated (500U/mL or U500) insulin aspart formulation, maintained its ultra-rapid pharmacokinetic and pharmacodynamic profile regardless of body mass index levels, supporting its potential as the first ultra-rapid U500 insulin for people with insulin-resistant type 2 diabetes who require high-dose therapy. This article marks the first time the complete study results have been published in a peer-reviewed scientific journal, following presentations at the annual meeting of the European Association for the Study of Diabetes and the American Diabetes Association's Scientific Sessions.
Crism Therapeutics Corporation 10.50p £7.92m (CRTX.L)
The UK clinical-stage drug delivery Company focused on the localised and sustained delivery of chemotherapy drugs confirms that the Site Initiation Visit at the lead NHS clinical trial site has now completed successfully. The Company is working closely with the clinical site, NHS Trust and its clinical partners to enable patient recruitment to commence in the coming weeks. The Phase II study will evaluate irinotecan ChemoSeed, the Company's proprietary implantable drug delivery technology designed to provide sustained, localised delivery of irinotecan directly into the tumour margin following surgical resection of a glioblastoma tumour.
Distil 0.06p £1.02m (DIS.L)
The owner of premium drinks brands including RedLeg Spiced Rum, Blackwoods Gin and Vodka, and Blavod Black Vodka, has received the first order through its U.S. distribution partner to bring Blavod Black Vodka back into the U.S. market. The first shipment is substantial and expected to leave the UK early in Q3 (of the current financial period ending 31 March 2027), with the new distribution partner boasting an extensive distribution network across the U.S., Canada and Puerto Rico. Vodka represents the biggest spirit category in the U.S. by volume and value, one of the biggest spirits markets globally based on 2024 and 2025 figures from IWSR Drinks Market Analysis.
Light Science Technologies Holdings 1.45p £15.89m (LST.L)
The technology and manufacturing business providing real-world solutions targeting issues including fire safety and global food security announces its unaudited interim results for the six months ended 31 May. This was a transformational Period, during which LSTH raised £6.6m (£6.1m net), leading to the completion of three strategic acquisitions that are now materially reshaping the Group's operational footprint. As expected, H1 was a period of consolidation with anticipated external delays impacting trading especially within the PFP division. As expected, PFP applications accelerated towards the end of the Period with levels of pipeline conversion dramatically increasing - per the increasing demand for the Group's services both as an installer and supplier of Injectaclad. The Company recorded revenue of £3.73m (H1 2025: £5.06m) with a gross margin of 30.5% (H1 2025: 36.3%), while total group cash and undrawn working capital facilities at 31 May was £2.72m (£2.44m cash and £0.28m undrawn facilities).
Marechale Capital 5.85p £12.86m (MAC.L)
The AIM-quoted digital merchant bank announced the launch of a tokenised reef programme by Coral Futures Corporation on Blubird's newly launched, second-generation tokenisation platform, digital asset registry and marketplace. Blubird, a wholly-owned subsidiary of the Group, is initially hosting a pilot registration of natural capital assets, comprising c.124,400 individually recorded sections of living cultivated coral located in Western Australia. Each section measures one square metre and the pilot registration has a total value of US$118m. The programme has been structured to scale to a further two million sections of reef interests under registry administration at full build-out, with an estimated aggregate value of approximately US$2bn.
Neoterra Group 2.20p £8.92m (TERA.L)
The African critical minerals exploration and development Company received preliminary results from Comex and SGS Lakefields for gallium ore sorting and hydrometallurgy respectively. Comex tested the suitability of Short-Wave Infra-Red and X-Ray Transmission for pre-concentration of gallium-bearing feldspar. The results of the XRT testing show that XRT technology successfully allows the identification and separation of feldspar (which carries gallium and represents about 30% of the rock mass) from other minerals, providing a pathway for gallium pre-concentration. SGS carried out initial gallium extraction testing using both acid and caustic leaching routes. The acid route delivered promising results, with 85% gallium extraction to the leachate, and a good selectivity against silica. The results reported are initial, and further metallurgical work will be necessary to confirm the potential viability of gallium recovery at Monte Muambe.
Oxford BioDynamics 0.14p £5.58m (OBD.L)
The international biotechnology Company advancing personalised healthcare through precision clinical diagnostic tests and EpiSwitch Orion, its cloud-based 3D genomics platform for pharma and biotech partners, has entered into a partnership agreement with The Dubai London Clinics & Hospitals Group. This agreement makes OBD's EpiSwitch PSE prostate cancer test available across DLCH's network of clinics and hospitals across the United Arab Emirates. Under the agreement, patient blood samples will be collected at DLCH facilities and processed at OBD's laboratory in the UK. The end-to-end clinical workflow has been successfully validated between the two organisations.
Shuka Minerals 2.90p £3.95m (SKA.L)
The African focused mine operator and developer has successfully completed the ninth drill hole KBDD09 slightly to the south of the previously unmined "Speaks" and "Mine Club" zones at the Kabwe Zinc Mine. The Company and consultants, GeoQuest, intersected a previously unknown, near surface, orebody a few hundred metres south of the Speaks and Mine Club areas. KBDD09 represents the first of three exploratory drill holes, targeting this new ore body. Lead is present as values ranging 0.1-12.3% Pb. Copper and vanadium grades were also detected consistent with the historically reported copper oxide and vanadium oxide mineralisation. The Behre Dolbear 2023 NI 43-101 report indicates that the Speaks orebody contains 1.944m tonnes of indicated and inferred resource at grades of 12% Zn and 2% Pb.
tinyBuild Inc 10.5p £43.3m (TBLD.L)
tinyBuild, a premium video games publisher and developer with global operations, announces that, on 11 August, it filed a lawsuit against Max Ent Games Ltd. (formerly Merge Games) in the United States District Court for the Western District of Washington regarding unpaid royalties relating to the game Smalland. tinyBuild alleges Max failed to pay royalties owed to tinyBuild. Max acknowledged royalties are due, but the parties disagree regarding how to calculate the royalties owed. tinyBuild alleges that the full amount due by Max exceeds $1.9m, before interest and legal costs.
AQSE Market
B HODL 5.00p 6.97m (AQSE:HODL)
The first British company founded to Buy, Hold, Deploy and Compound Bitcoin, has signed a non-binding letter of intent with Zeus Wallet, the first step in a new commercial relationship. Under the letter of intent B HODL will connect its Lightning Network routing capacity to ZEUS's node infrastructure, adding liquidity and routing strength for users of the ZEUS Wallet and earning the Company Bitcoin routing fees in return. As at the date of this announcement, BHODL and Zeus have already opened an initial channel with 1 BTC capacity, with the parties reviewing performance after three months and intending to scale the deployment of liquidity further should that review support broader collaboration.
What’s baking in the oven?
Potential IPOs:***
Dual List:***
5th August: 1947 Oil & Gas, the newly incorporated oil and gas production Company focused on acquiring, operating and growing a portfolio of producing assets in the US, announced its intention to IPO onto AIM. In connection with Admission, the Company has entered into a conditional agreement to acquire Renaissance Offshore, LLC, a privately held, Houston-based oil and gas production company with interests in eleven fields located in the shallow-water Gulf of America. The Company is raising gross proceeds of £50m and the expected market capitalisation of the Company on Admission will be £65m. Admission is expected to occur in August 2026.
3rd August: Africa Bitcoin Corporation has announced its intention to dual list onto the AQSE Market. The company is a financial services group with a Bitcoin Treasury Strategy dedicated to providing financial services to SMEs across South Africa with a broad suite of solutions. The Company has a primary listing on the Main Board of the Johannesburg Stock Exchange and secondary listings on the A2X Proprietary Limited and the Namibia Securities Exchange and its ordinary shares also trade on OTCQB Market in the US and the Frankfurt Stock Exchange. Expected Admission date is 17th August.
Reverse Takeovers:***
4th August: Vast Resources (VAST.L), the mining exploration, development and production company, with assets in Tajikstan and Tomania, has proposed a reverse takeover of Gulf International Minerals, which holds a 49% stake in the Aprelevka JV in Tajikistan, alongside the Tajik government's 51%. The company intends to complete the transaction via an all-share consideration deal with Bay Square Pacific and its shareholders. Alongside the Acquisition, the Company has conditionally raised gross proceeds of £5.9m by way of a placing of 94,400,000 new ordinary shares and a subscription for 26,359,826 new ordinary shares, in each case at 6.25p per share. The Company also intends to launch a retail offer. The expected date of admission is 19 August 2026.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
